Glutamatergic transmission aberration: A major cause of behavioral deficits in a murine model of down's syndrome

Journal of Neuroscience

Volumn 34, Issue 15, 2014, Pages 5099-5106

  Kaur, Gurjinder ^a   Sharma, Ajay ^a   Xu, Wenjin ^a,b   Gerum, Scott ^a   Alldred, Melissa J ^a,b   Subbanna, Shivakumar ^a   Basavarajappa, Balapal S ^a,d   Pawlik, Monika ^a   Ohno, Masuo ^a,b   Ginsberg, Stephen D ^a,b,c   Wilson, Donald A ^a,b   Guilfoyle, David N ^a   Levy, Efrat ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Department of Child and Adolescent Psychiatry ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Biochemistry and Molecular Pharmacology ^*  (United States)

Author keywords

Down's syndrome; Glutamate; LTP; NMDA receptors; Spatial memory

Indexed keywords

2 AMINOBUTYRIC ACID; BETA TUBULIN; CREATINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; FEMALE; FUNCTIONAL DISSOCIATION; HOUSEKEEPING GENE; INTELLECTUAL IMPAIRMENT; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NESTING; NEUROTRANSMISSION; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME POLYMERASE CHAIN REACTION; SPATIAL MEMORY TEST; SYNAPTIC INHIBITION; TASK PERFORMANCE; WESTERN BLOTTING; Y-MAZE TEST;

DOWN'S SYNDROME; GLUTAMATE; LTP; NMDA RECEPTORS; SPATIAL MEMORY;

ANIMALS; CA1 REGION, HIPPOCAMPAL; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; GLUTAMIC ACID; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; MICE; NESTING BEHAVIOR; NEURONS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SYNAPSES;

EID: 84899494039     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5338-13.2014     Document Type: Article

References (74)

1. Alldred MJ, Che S, Ginsberg SD (2008) Terminal Continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci 9:2091-2104. CrossRef Medline
2. Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis 45:751-762. CrossRef Medline
3. Bar-Peled O, Gross-Isseroff R, Ben-Hur H, Hoskins I, Groner Y, Biegon A (1991) Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci Lett 127:173-176. CrossRef Medline
4. Basavarajappa BS, Subbanna S (2014) CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 24:178-188. CrossRef Medline.
5. Best TK, Cramer NP, Chakrabarti L, Haydar TF, Galdzicki Z (2012) Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp Neurol 233:749-757. CrossRef Medline
6. Bhattacharyya A, McMillan E, Chen SI, Wallace K, Svendsen CN (2009) A critical period in cortical interneuron neurogenesis in Down syndrome revealed by human neural progenitor cells. Dev Neurosci 31:497-510. CrossRef Medline
7. Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, Costa AC (2012) Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2:e141. CrossRef Medline
8. Bottomley PA (1987) Spatial localization inNMRspectroscopy in vivo. Ann N Y Acad Sci 508:333-348. CrossRef Medline
9. Canas PM, Simões AP, Rodrigues RJ, Cunha RA (2014) Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease. Neuropharmacology 76:51-56. CrossRef Medline
10. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.AmJ Pathol 157:277-286. CrossRef Medline
11. Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, Buckmaster P, Garner CC, Heller HC (2013) Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained procognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol 169:963-973. CrossRef Medline
12. Costa AC, Scott-McKean JJ, Stasko MR (2008) Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33:1624-1632. CrossRef Medline
13. Cramer N, Galdzicki Z (2012) From abnormal hippocampal synaptic plasticity in Down syndrome mouse models to cognitive disability in Down syndrome. Neural Plast 2012:101542. CrossRef Medline
14. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503-1506. CrossRef Medline
15. Danysz W, Parsons CG (2012) Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol 167:324-352. CrossRef Medline
16. Das I, Reeves RH (2011) The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 4:596-606. CrossRef Medline
17. Davisson MT, Schmidt C, Akeson EC (1990) Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 360:263-280. Medline
18. Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1:1117-1119. CrossRef Medline
19. Deacon RM, Croucher A, Rawlins JN (2002) Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res 132:203-213. CrossRef Medline
20. Devi L, Alldred MJ, Ginsberg SD, Ohno M (2010) Sex- and brain regionspecific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol Brain 3:34. CrossRef Medline
21. Duszczyk M, Ziembowicz A, Gadamski R, Lazarewicz JW (2006) Behavioral evaluation of ischemic damage to CA1 hippocampal neurons: effects of preconditioning. Acta Neurobiol Exp 66:311-319. Medline
22. Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A (2013) Amyloidβ, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 19:549-555. CrossRef Medline
23. Filali M, Lalonde R (2009) Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-99. CrossRef Medline
24. Filali M, Lalonde R, Rivest S (2011) Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 60:930-936. CrossRef Medline
25. Ginsberg SD (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439:147-158. CrossRef Medline
26. Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M (1987) Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 50:775-778. CrossRef Medline
27. Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161:647-663. CrossRef Medline
28. Gruetter R (1993) Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med 29:804-811. CrossRef Medline
29. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C (2012) Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebocontrolled trial. Lancet 379:528-536. CrossRef Medline
30. Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L, Shamloo M, Sheng M, Scearce-Levie K, Zhou Q (2013) GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology 38: 1221-1233. CrossRef Medline
31. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93:13333-13338. CrossRef Medline
32. Hughes RN (2004) Responsiveness to brightness change in maleandfemale rats following treatment with the partial agonist of the N-methyl-D-aspartate receptor, D-cycloserine. Behav Brain Res 152:199-207. CrossRef Medline
33. Hynd MR, Scott HL, Dodd PR (2004) Selective loss ofNMDAreceptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem 89:240-247. CrossRef Medline
34. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736. CrossRef Medline
35. Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S (2008) Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29:1619-1630. CrossRef Medline
36. Kirvell SL, Esiri M, Francis PT (2006) Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98:939-950. CrossRef Medline
37. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24:8153-8160. CrossRef Medline
38. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC (2012) Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 32:9217-9227. CrossRef Medline
39. Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296-304. CrossRef Medline
40. Levine S, Saltzman A, Levy E, Ginsberg SD (2009) Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86:18-22. CrossRef Medline
41. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC (2011) Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221:610-622. CrossRef Medline
42. Lott IT (2012) Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 197:101-121. CrossRef Medline
43. Lott IT, Dierssen M (2010) Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9:623-633. CrossRef Medline
44. Luine VN, Jacome LF, Maclusky NJ (2003) Rapid enhancement of visual and place memory by estrogens in rats. Endocrinology 144:2836-2844. CrossRef Medline
45. Macbeth AH, Gautreaux C, Luine VN (2008) Pregnant rats show enhanced spatial memory, decreased anxiety, and altered levels of monoaminergic neurotransmitters. Brain Res 1241:136-147. CrossRef Medline
46. Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á, Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Hernández MC (2013) Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome. J Neurosci 33:3953-3966. CrossRef Medline
47. Oka A, Takashima S (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 97: 275-278. CrossRef Medline
48. Parsons CG, Stöffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53:699-723. CrossRef Medline
49. Paxinos G, Franklin KBJ (2000) The mouse brain in stereotaxic coordinates. Ed 3. San Diego: Academic.
50. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L (2003) The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 74:75-93. CrossRef Medline
51. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83-89. CrossRef Medline
52. Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795-811. CrossRef Medline
53. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo protonNMRspectra. Magn Reson Med 30:672-679. CrossRef Medline
54. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341. CrossRef Medline
55. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49-54. CrossRef Medline
56. Reynolds GP, Warner CE (1988) Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neurosci Lett 94:224-227. CrossRef Medline
57. Risser D, Lubec G, Cairns N, Herrera-Marschitz M (1997) Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 60:1231-1237. CrossRef Medline
58. Rueda N, Flórez J, Martínez-Cué C (2012) Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast 2012:584071. CrossRef Medline
59. Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R (1986) Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19:263-269. CrossRef Medline
60. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG (2013) Amyloid-β 1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci 33:5312-5318. CrossRef Medline
61. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR (2011) Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging 32:553.e1-511. CrossRef Medline
62. Scott-McKean JJ, Costa AC (2011) Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem 18:774-778. CrossRef Medline
63. Sheehan R, Ali A, Hassiotis A (2014) Dementia in intellectual disability. Curr Opin Psychiatry 27:143-148. CrossRef Medline
64. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z (1999) Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38:1917-1920. CrossRef Medline
65. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, Klann E, Galdzicki Z (2006) Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 98:1266-1277. CrossRef Medline
66. TkÁc I, Starcuk Z, Choi IY, Gruetter R (1999) In vivo 1HNMRspectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41:649-656. CrossRef Medline
67. Villar AJ, Belichenko PV, Gillespie AM, Kozy HM, Mobley WC, Epstein CJ (2005) Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm Genome 16:79-90. Medline
68. Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol 33:636-642. CrossRef Medline
69. Wesson DW, Wilson DA (2011) Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res 216:408-413. CrossRef Medline
70. Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N (2007) Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 120:e1465-1471. CrossRef Medline
71. Wisniewski KE, Laure-Kamionowska M, Wisniewski HM (1984) Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. N Engl J Med 311:1187-1188. CrossRef Medline
72. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:278-282. CrossRef Medline
73. Yates CM, Simpson J, Gordon A (1986) Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci Lett 65:189-192. CrossRef Medline
74. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol 64:355-405. CrossRef Medline